Umoja Biopharma’s Colorado Momentum
The mission-driven team at Umoja Biopharma is advancing next-generation in vivo CAR T therapies. Recently named as “Company of the Year” at Colorado BioScience Association’s 22nd Annual Awards Celebration Presented by AGC Biologics, Umoja’s Colorado footprint includes the CLIMB, a 146,000-square-foot, commercial-ready lentiviral vector development and manufacturing facility in Louisville. The co-location of labs and manufacturing accelerates innovation and shortens the path from research to patients.
“Louisville, Colorado, provides a unique combination of highly educated and skilled talent, unparalleled work-life balance, and a supportive community that makes it the perfect location for our lentiviral vector development and manufacturing facility,” says Sally Dyer, SVP and General Manager at Umoja Biopharma.
Capital fuels that momentum. Umoja raised a $210 million Series B and a $100 million Series C in 2021 and 2025 respectively to advance its in vivo CAR T-cell pipeline through key clinical milestones. Investors see promise in platforms designed to expand access to cell therapy.
In 2025, Umoja Biopharma earned FDA Fast Track designation for its lead oncology program and was named one of 2025’s most promising biotech companies by both Endpoints News and Fierce Biotech, honors awarded to only a select few companies each year.
The company also supports the next generation of life sciences talent in Colorado. Umoja is an industry partner for the P-TECH program, supported by Colorado BioScience Institute. The program welcomes high-school students into hands-on internships that build real-world skills and open doors to careers in biomanufacturing. The Institute’s classroom programs and P-TECH partners help students earn industry-relevant experience while earning a high-school diploma and an associate’s degree from Aims Community College.
BNBuilders was proud to support an 18,000-square-foot tenant improvement project that created new office space on the second floor of the company’s recently built cGMP manufacturing facility.
